CEL-SCI Corporation (CVM)
| Market Cap | 12.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.27M |
| Shares Out | 5.14M |
| EPS (ttm) | -12.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,491 |
| Open | 2.470 |
| Previous Close | 2.440 |
| Day's Range | 2.370 - 2.470 |
| 52-Week Range | 1.980 - 66.597 |
| Beta | 0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2025 |
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections,... [Read more]
Financial Performance
Financial StatementsNews
FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HNSCC--FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine.
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of public offering.
CEL-SCI Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of public offering.
CEL-SCI Announces Proposed Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces proposed public offering.
CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI'S Multikine investigational cancer medicine potentially available for commercialization by summer 2025 in Saudi Arabia.
CEL-SCI Announces Combination of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces combination of common stock.
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal second quarter 2025 financial results.
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market.
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--New study in the scientific journal “Cancer Cell” supports CEL-SCI's strategy to seek early approval for Multikine.
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.
CEL-SCI Announces Closing of $2.5 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $2.5 million offering .
CEL-SCI Announces Pricing of $2.5 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $2.5 million offering.
CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Head and Neck Cancer Registration Study Protocol clears FDA review—in talks with potential partners Interested in commercialization of Multikine.
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows pre-surgical tumor elimination and regression in just 3 weeks.
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck cancer.
CEL-SCI Announces Closing of $5 Million Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $5 million offering.
CEL-SCI Announces Pricing of $5 Million Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $5 million public offering.
CEL-SCI Announces Proposed Public Offering of Common Stock
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces proposed public offering of common stock.
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.
Stock Picks From Seeking Alpha's October 2024 New Analysts
In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, ...
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--FDA's ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.